SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(RULE 13D-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13D-1(B), (C), AND (D) AND AMENDMENTS
THERETO FILED PURSUANT TO RULE 13D-2
(AMENDMENT NO. 1)*
Acadia Pharmaceuticals Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
0042251084
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2005
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|_| Rule 13d-1(c)
|X| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the NOTES).
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Oxford Bioscience Partners IV L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
mNRA Fund II L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OBP Management IV L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 share
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Jeffrey T. Barnes
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Mark P. Carthy
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Jonathan J. Fleming
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Michael E. Lytton
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,422,717 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFCATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Alan G. Walton
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 29,084 shares
--------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 3,422,717 shares
--------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 29,084 shares
--------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 3,422,717 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
3,451,801 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
IN
--------------------------------------------------------------------------------
SCHEDULE 13G
ITEM 1(A). NAME OF ISSUER: The name of the issuer is Acadia Pharmaceuticals
Inc. (the "Issuer").
ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Issuer's
principal executive offices are located at 3911 Sorrento Valley Boulevard, San
Diego, California, 92121.
ITEM 2(A). NAME OF PERSON FILING
This Statement on Schedule 13G is being filed on behalf of: (i) Oxford
Bioscience Partners IV L.P. ("Oxford IV"), a Delaware limited partnership; (ii)
mRNA Fund II L.P. ("mRNA II"), a Delaware limited partnership; (iii) OBP
Management IV L.P. ("OBP IV"), a Delaware limited partnership, the general
partner of Oxford IV and mRNA II; (iv) Jeffrey T. Barnes, a general partner of
OBP IV; (v) Mark P. Carthy, a general partner of OBP IV; (vi) Jonathan J.
Fleming, a general partner of OBP IV; (vii) Michael E. Lytton, a general partner
of OBP IV; and (viii) Alan G. Walton, a general partner of OBP IV (all general
partners are referred to collectively as the "General Partners"). Collectively,
all of the above listed entities and persons are referred to as the "Reporting
Persons."
ITEM 2(B). ADDRESS OF PRINCIPAL BSINESS OFFICE OR, IF NONE, RESIDENCE: The
address for all reporting persons is 222 Berkeley Street, Boston, MA 02116.
ITEM 2(C). CITIZENSHIP: Oxford IV, mRNA II and OBP IV are Delaware limited
partnerships and the General Partners are citizens of the United States.
ITEM 2(D). TITLE OF CLASS OF SECURITIES: Title of Class of Securities: Common
Stock, $0.0001 par value.
ITEM 2(E). CUSIP NUMBER: 0042251084
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR
(C), CHECK WHETHER THE PERSON FILING IS A:
(a) |_| Broker or dealer registered under section 15 of the Exchange Act.
(b) |_| Bank as defined in section 3(a)(6) of the Exchange Act.
(c) |_| Insurance company as defined in section 3(a)(19) of the Exchange
Act.
(d) |_|Investment company registered under section 8 of the
Investment Company Act.
(e) |_| An investment adviser in accordance with Rule13d-1(b)(1)(ii)(E);
(f) |_| An employee benefit plan or endowment fund in accordance with Rule
13d-1(b)(1)(ii)(F);
(g) |_| A parent holding company or control person in accordance with Rule
13d-1(b)(1)(ii)(G);
(h) |_| A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act;
(i) |_| A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company
Act;
(j) |_| Group, in accordance with Rule13d-1(b)(1)(ii)(J).
Not applicable.
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: As of December 31, 2005 each of the
following is the owner of record of the number of shares of Common
Stock, $0.0001 of Acadia Pharmaceuticals Inc. set forth next to his
or its name:
Oxford IV: 3,396,738 Shares
mRNA II: 25,979 Shares
OBP IV: 0 Shares
Mr. Barnes: 0 Shares
Mr. Carthy: 0 Shares
Mr. Fleming: 0 Shares
Mr. Lytton: 0 Shares
Mr. Walton: 29,084 Shares
By virtue of their relationship as affiliated limited partnerships,
whose sole general partner shares individual general partners,
Oxford IV and mRNA II may be deemed to share voting power and the
power to direct the disposition of the shares which each partnership
owns of record. OBP IV (as the general partner of Oxford IV and mRNA
II), may also be deemed to own beneficially the shares held of
record by Oxford IV and mRNA II. Each of Messrs. Barnes, Carthy,
Fleming, Lytton, and Walton, the individual general partners of OBP
IV, may be deemed to own beneficially the shares held by Oxford IV
and mRNA II.
(b) Percent of Class:
Oxford IV: 14.6%
mRNA II: 14.6%
OBP IV: 14.6%
Mr. Barnes: 14.6%
Mr. Carthy: 14.6%
Mr. Fleming: 14.6%
Mr. Lytton: 14.6%
Mr. Walton: 14.6%
The foregoing percentages are calculated based on the 23,488,317
shares of Common Stock reported to be outstanding as of November 14,
2005 in the Quarterly Report on Form 10-Q of Acadia Pharmaceuticals
Inc. for the quarter ended September 30, 2005 (as adjusted pursuant
to Rule 13d-3(d)(1)).
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
Oxford IV: 0 Shares
mRNA II: 0 Shares
OBP IV: 0 Shares
Mr. Barnes: 0 Shares
Mr. Carthy: 0 Shares
Mr. Fleming: 0 Shares
Mr. Lytton: 0 Shares
Mr. Walton: 29,084 Shares
(ii) shared power to vote or to direct the vote:
Oxford IV: 3,422,717 Shares
mRNA II: 3,422,717 Shares
OBP IV: 3,422,717 Shares
Mr. Barnes: 3,422,717 Shares
Mr. Carthy: 3,422,717 Shares
Mr. Fleming: 3,422,717 Shares
Mr. Lytton: 3,422,717 Shares
Mr. Walton: 3,422,717 Shares
(iii) sole power to dispose or to direct the disposition of:
Oxford IV: 0 Shares
mRNA II: 0 Shares
OBP IV: 0 Shares
Mr. Barnes: 0 Shares
Mr. Carthy: 0 Shares
Mr. Fleming: 0 Shares
Mr. Lytton: 0 Shares
Mr. Walton: 29,084 Shares
(iv) shared power to dispose or to direct the disposition of:
Oxford IV: 3,422,717 Shares
mRNA II: 3,422,717 Shares
OBP IV: 3,422,717 Shares
Mr. Barnes: 3,422,717 Shares
Mr. Carthy: 3,422,717 Shares
Mr. Fleming: 3,422,717 Shares
Mr. Lytton: 3,422,717 Shares
Mr. Walton: 3,422,717 Shares
Each of Oxford IV, mRNA II, OBP IV, and Messrs. Barnes, Carthy,
Fleming, Lytton and Walton expressly disclaims beneficial ownership
of any shares of the Common Stock of Acadia Pharmaceuticals Inc.,
except for the shares, if any, such Reporting Persons hold of
record.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable. Oxford IV, mRNA II, OBP IV, Messrs. Barnes, Carthy, Fleming,
Lytton and Walton expressly disclaim membership in a "group" as used in Rule 13d
1(b)(ii)(J) of the Act.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
By signing below each of Oxford IV, mRNA II, OBP IV, and Messrs. Barnes,
Carthy, Fleming, Lytton and Walton certify that, to the best of its or his
knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of his, her or its knowledge and
belief, each of the undersigned certifies that the information set forth in this
statement is true, complete and correct. We also hereby agree to file this
statement jointly pursuant to the agreement set forth as EXHIBIT 1.
Dated: February 9, 2006
OXFORD BIOSCIENCE PARTNERS IV L.P.
By: OBP Management IV L.P., its general
partner
By: *
-------------------------------
Jonathan J. Fleming
General Partner
MRNA FUND II L.P.
By: OBP Management IV L.P., its general
partner
By: *
-------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT IV L.P.
By: *
-------------------------------
Jonathan J. Fleming
General Partner
*
-------------------------------
Jeffrey T. Barnes
*
-------------------------------
Mark P. Carthy
*
-------------------------------
Jonathan J. Fleming
*
-------------------------------
Michael E. Lytton
*
-------------------------------
Alan G. Walton
By: /S/ RAYMOND CHAREST
--------------------------
Raymond Charest as Attorney-in-Fact
This Schedule 13G was executed by Raymond Charest pursuant to the Power of
Attorney attached hereto as EXHIBIT 2.
EXHIBIT 1
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of Acadia Pharmaceuticals Inc.
Dated: February 9, 2006
OXFORD BIOSCIENCE PARTNERS IV L.P.
By: OBP Management IV L.P., its general
partner
By: *
-------------------------------
Jonathan J. Fleming
General Partner
MRNA FUND II L.P.
By: OBP Management IV L.P., its general
partner
By: *
-------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT IV L.P.
By: *
-------------------------------
Jonathan J. Fleming
General Partner
*
-------------------------------
Jeffrey T. Barnes
*
-------------------------------
Mark P. Carthy
*
-------------------------------
Jonathan J. Fleming
*
-------------------------------
Michael E. Lytton
*
-------------------------------
Alan G. Walton
By: /S/ RAYMOND CHAREST
--------------------------
Raymond Charest as Attorney-in-Fact
This Schedule 13G was executed by Raymond Charest pursuant to the Power of
Attorney attached hereto as EXHIBIT 2.
EXHIBIT 2
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below hereby constitutes and appoints Raymond Charest, Alexia Pearsall and
Jonathan J. Fleming, and each of them, with full power to act without the other,
his true and lawful attorney-in-fact and agent, with full power of substitution,
for him and in his name, place and stead, in any and all capacities (until
revoked in writing) to sign any and all instruments, certificates and documents
required to be executed on behalf of himself as an individual or in his capacity
as a general partner or authorized signatory, as the case may be, on behalf of
any of Oxford Bioscience Partners IV L.P., mRNA II L.P., or OBP Management IV
L.P., pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), and any and all regulations promulgated thereunder
and to file the same, with all exhibits thereto, and any other documents in
connection therewith, with the Securities and Exchange Commission, and with any
other entity when and if such is mandated by the Exchange Act or by the By-laws
of the National Association of Securities Dealers, Inc., granting unto said
attorney-in-fact and agent full power and authority to do and perform each and
every act and thing requisite and necessary fully to all intents and purposes as
he might or could do in person thereby ratifying and confirming all that said
attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or
cause to be done by virtue hereof, or may have done in connection with the
matters described above.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 8th day of
April, 2004.
OXFORD BIOSCIENCE PARTNERS IV L.P.
BY ITS GENERAL PARTNER, OBP MANAGEMENT IV L.P.
By: /S/ JONATHAN J. FLEMING
------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
MRNA FUND II L.P.
BY ITS GENERAL PARTNER, OBP MANAGEMENT IV L.P.
By: /S/ JONATHAN J. FLEMING
------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
OBP MANAGEMENT IV L.P.
By: /S/ JONATHAN J. FLEMING
---------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
/S/ JEFFREY T. BARNES
----------------------------------------
Jeffrey T. Barnes
/S/ MARK P. CARTHY
----------------------------------------
Mark P. Carthy
/S/ JONATHAN J. FLEMING
----------------------------------------
Jonathan J. Fleming
/S/ MICHAEL E. LYTTON
----------------------------------------
Michael E. Lytton
/S/ ALAN G. WALTON
----------------------------------------
Alan G. Walton